Project Grant R21CA290426
Award Date
1/1/25
Completion Date
12/31/26
Dollars Obligated
$180K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Stanford, CA 94305, USA
Similar Awards
This Project Grant award for $138,240 from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) will fund research at Weill Medical College of Cornell University to define novel mechanisms by which the microbiota (gut microbes) regulate anti-tumor immune responses and immunotherapy outcomes. The research aims to elucidate how host-microbiota interactions promote tumor growth and progression, as well as shape systemic anti-tumor immunity and response to...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $684,367 to Baylor College of Medicine to conduct research investigating intratumoral microbiota and immune predictors of response to immunotherapy in lung cancer. The key objectives are to:
Identify intratumoral microbiome profiles predictive of response to immune checkpoint inhibitor (ICI) therapy, using whole-metagenome sequencing.
Characterize spatial immune signatures...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering under the Discovery and Applied Research for Technological Innovations to Improve Human Health (CFDA 93.286) federal grant program is funding research to develop a "three-cell (T-NK-macrophage) synthetic immunotherapy system" for cancer treatment. The $207,900 award to The Leland Stanford Junior University aims to screen libraries of chimeric antigen receptors (CARs) and synthetic cytokine...
This Project Grant award of $400,890, provided by the National Cancer Institute (CFDA 93.396 Cancer Biology Research), supports research to profile patient-specific tumor-microbiome interactions and conduct molecular analyses to elucidate microbiome-mediated modulation of immune checkpoint molecules in mismatch repair-proficient, microsatellite-stable colorectal tumors. The research team at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University will utilize...
This $654,763 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to define the mechanistic basis of how gut microbiome-produced androgen metabolites can promote resistance to androgen receptor-targeted therapies and dampen anti-tumor immunity in metastatic prostate cancer. The awardee, The Johns Hopkins University, will investigate whether microbial-derived androgens are sufficient to mediate therapy resistance, determine...
This $678,399 Project Grant award was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program to The University of Texas MD Anderson Cancer Center. The funding will support a research study to evaluate the impact of a prebiotic diet intervention combined with standard immune checkpoint inhibitor (ICI) therapy in patients with metastatic melanoma.
The study aims to investigate whether the prebiotic diet intervention can modulate the...
This $530,612 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) aims to investigate the role of the gut microbiome in melanoma progression and prevention of lymph node metastasis. The key research objectives are to: 1) Identify gut microbial and immunologic features associated with tumor progression and lymph node metastasis in melanoma patients, and 2) Determine strategies to modulate the gut microbiome to prevent melanoma progression and...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under CFDA 93.847 "Diabetes, Digestive, and Kidney Diseases Extramural Research" will provide $364,324 to The Leland Stanford Junior University to conduct research on understanding how microbially-derived metabolites regulate host gut inflammation. The award period runs from August 28, 2024 to February 28, 2027.
The research aims to 1) determine the regulatory role of...
This federal Project Grant award for $281,606, provided by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower), will fund research conducted by Dr. Rabi Upadhyay at New York University (NYU) School of Medicine to investigate how specific gut bacteria can drive anti-tumor immunity in lung cancer. The research aims to elucidate the mechanisms by which gut colonization with certain Bacteroides commensals can lead to systemic anti-tumor effects, even in the absence of...
This federal Project Grant award, identified as R35GM155437, was provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859). The $386,000 grant supports research conducted by The Leland Stanford Junior University to advance the applications of engineered multicellular systems, particularly in engineered T cells targeting solid tumors. The research aims to 1) engineer highly specific cellular recognition...